丹参酮ⅡA磺酸钠注射液对冠心病病人血尿酸水平的影响

The Influence of Sulfotanshinone Sodium Injection on Serum Uric Acid Levels in Coronary Heart Disease

目的观察应用丹参酮ⅡA磺酸钠注射液治疗1周及2周后冠心病病人血尿酸水平的变化。方法将330例冠心病病人分为治疗组与对照组。治疗组234例,其中无症状高尿酸血症病人109例,为1组,血尿酸水平正常者125例,为2组;对照组96例,其中无症状高尿酸血症病人42例,为3组,血尿酸水平正常者56例,为4组。所有病人入院当日或次日测量静脉血尿酸水平,1周后及2周后分别复查静脉血尿酸水平。比较治疗前后各组血尿酸水平的变化。结果各组病人治疗1周及2周后尿酸水平均有下降,1组下降最明显,与其他3组比较差异有统计学意义(P<0.05或P<0.01)。结论丹参酮ⅡA磺酸钠注射液对无症状高尿酸血症的冠心病病人有降低血尿酸水平的作用。

Objective To investigate the effect of sulfotanshinone sodium injection（SSI） on serum uric acid levels in patients （pts） with coronary heart disease. Methods Three hundreds and thirty pts with coronary heart disease were divided into four groups. Group I （109 pts with elevated serum uric acid） and group 2（n=125） were treated with SSI for two weeks. Croup 3 （42 pts with elevated serum uric acid） and group 4（n=56） were treated with routine treatment. Serum uric acid levels were tested at admission,and following treatment for one week and two weeks. Results After treatment for one week and two weeks, the levels of serum uric acid were decreased in all pts,but the level of serum uric acid in group 1 was decreased significantly compared with other groups（P〈0.05 or P〈 0.01）. Conclosion SSI was effective to reduce serum uric acid level in pts with coronary heart disease.